Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 5K | 10K | 5K | 3M | 398K |
| Gross Profit | 5K | 10K | -5M | 3M | 398K |
| Operating Income | -4M | -5M | -34M | -35M | -78M |
| EBITDA | -4M | -5M | -31M | -32M | -75M |
| Net Income | -4M | -5M | -35M | -38M | -79M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$2.26
+2.26% today
1Y Change
-49.88%
Window
Jun 20, 2025 → Jun 18, 2026
Coverage: 250 bars · Jun 20, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Alaunos Therapeutics, Inc. (TCRT) is a Healthcare stock with a market cap of $10.00M and listed on NASDAQ. The stock last traded around $2.26 and down 49.9% across the available one-year price window (Jun 20, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of -50.0%, EPS growth of +24.7%, a dividend yield of 0.0%. What stands out right now is revenue -50.0%, EPS +24.7%, free cash flow +40.3% with operating margin -84500.0% and ROIC -196.2%. Valuation already assumes a fairly strong business story at price/sales 1241.4. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines TCRT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TCRT
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TCRT Max Drawdown
-65.50%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TCRT and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$398.0K
-86.4% YoY
FY Net Income
-$78.8M
-108.7% YoY
Free Cash Flow
-$64.8M
-120.0% YoY
Revenue Growth
-50.0%
EPS Growth
+24.7%
Gross Margin
-3600.0%
Net Margin
-83520.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 5K | 10K | 5K | 3M | 398K |
| Gross Profit | 5K | 10K | -5M | 3M | 398K |
| Operating Income | -4M | -5M | -34M | -35M | -78M |
| EBITDA | -4M | -5M | -31M | -32M | -75M |
| Net Income | -4M | -5M | -35M | -38M | -79M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 1M | 1M | 6M | 39M | 76M |
| Total Assets | 3M | 3M | 8M | 65M | 95M |
| Total Liabilities | 813K | 692K | 2M | 26M | 37M |
| Shareholder Equity | 2M | 2M | 6M | 39M | 58M |
| Total Debt | 0 | 0 | 0 | 20M | 30M |
| Net Debt | -1M | -1M | -6M | -19M | -46M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
61M
-110.3% YoY
Capital Expenditures
3M
-1438.4% YoY
Free Cash Flow
65M
-120.0% YoY
Key ratios
Gross Margin
-3600.0%
Operating Margin
-84500.0%
Net Margin
-83520.0%
ROE
-172.7%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.